Patent application number | Description | Published |
20090137002 | ANTI EPHB4 ANTIBODIES AND ANTIBODY FRAGMENTS - The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy. | 05-28-2009 |
20100119506 | Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation - The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation. | 05-13-2010 |
20110311553 | Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation - The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation. | 12-22-2011 |
Patent application number | Description | Published |
20090169601 | Transdermal Therapeutic System for Administering Lipophilic and/or Sparingly Skin- Permeable Active Substances - A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups:
| 07-02-2009 |
20100028412 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING WATER-SOLUABLE ACTIVE INGREDIENTS - The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure. | 02-04-2010 |
20110295184 | Preparation and Iontophoretic Device for the Transdermal Application of Active Ingredients - The present invention relates to an iontophorectic device and a composition comprising active ingredients for the transdermal release of active ingredients, particularly of human insulin. Insulin, a blood sugar-lowering hormone inhibiting glycogen breakdown of the pancreas, can be made available as the most important pharmaceutical for the therapy of diabetes mellitus via the transdermal resorption route. | 12-01-2011 |
20120316520 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING LIPOPHILIC AND/OR SPARINGLY SKIN-PERMEABLE ACTIVE SUBSTANCES - A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms. | 12-13-2012 |